Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay.

Lee SH, Chung AM, Lee A, Oh WJ, Choi YJ, Lee YS, Jung ES.

J Pathol Transl Med. 2017 Jan;51(1):24-31. doi: 10.4132/jptm.2016.10.03. Epub 2016 Dec 25.

2.

Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy.

Feng Y, Gao S, Gao Y, Wang X, Chen Z.

Oncotarget. 2016 Dec 6;7(49):81402-81409. doi: 10.18632/oncotarget.13233.

4.

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.

Richman SD, Fairley J, Butler R, Deans ZC.

J Clin Pathol. 2017 Jan;70(1):58-62. doi: 10.1136/jclinpath-2016-203822. Epub 2016 Sep 28.

6.

Current targeted therapies in the treatment of advanced colorectal cancer: a review.

Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P.

Ther Adv Med Oncol. 2016 Jul;8(4):276-93. doi: 10.1177/1758834016646734. Epub 2016 May 29. Review.

7.

Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy.

Chen Z, Gao S, Wang D, Song D, Feng Y.

Am J Transl Res. 2016 Feb 15;8(2):1190-6. eCollection 2016.

8.

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ.

Cancer Biol Ther. 2016 Jul 2;17(7):751-9. doi: 10.1080/15384047.2016.1178426. Epub 2016 Apr 22.

9.

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.

Yan Y, Grothey A.

Onco Targets Ther. 2015 Oct 15;8:2949-57. doi: 10.2147/OTT.S79145. eCollection 2015. Review.

10.

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A, Russo A.

Oncotarget. 2015 Sep 22;6(28):24780-96. doi: 10.18632/oncotarget.4959. Review.

11.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T.

Curr Oncol. 2015 Aug;22(4):e305-15. doi: 10.3747/co.22.2603. Erratum in: Curr Oncol. 2016 Aug;23(4):e435.

12.

Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.

Al-Shamsi HO, Alhazzani W, Wolff RA.

J Gastrointest Oncol. 2015 Jun;6(3):314-21. doi: 10.3978/j.issn.2078-6891.2015.016. Review.

13.

HGUE-C-1 is an atypical and novel colon carcinoma cell line.

Grasso S, Martínez-Lacaci I, Barberá VM, Castillejo A, Soto JL, Gallego-Plazas J, López-Riquelme N, García-Morales P, Mata-Balaguer T, Ferragut JA, Saceda M.

BMC Cancer. 2015 Apr 8;15:240. doi: 10.1186/s12885-015-1183-3.

14.

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.

Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM.

Cancer Prev Res (Phila). 2015 Mar;8(3):222-30. doi: 10.1158/1940-6207.CAPR-14-0148. Epub 2015 Jan 20.

15.

Modified simultaneous integrated boost radiotherapy for an unresectable huge refractory pelvic tumor diagnosed as a rectal adenocarcinoma.

Nomiya T, Akamatsu H, Harada M, Ota I, Hagiwara Y, Ichikawa M, Miwa M, Kawashiro S, Hagiwara M, Chin M, Hashizume E, Nemoto K.

World J Gastroenterol. 2014 Dec 28;20(48):18480-6. doi: 10.3748/wjg.v20.i48.18480.

16.

Genomic era diagnosis and management of hereditary and sporadic colon cancer.

Esplin ED, Snyder MP.

World J Clin Oncol. 2014 Dec 10;5(5):1036-47. doi: 10.5306/wjco.v5.i5.1036. Review.

17.

Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer.

Kircher SM, Mohindra N, Nimeiri H.

Oncologist. 2015 Jan;20(1):14-8. doi: 10.1634/theoncologist.2014-0252. Epub 2014 Nov 19.

18.

Effect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse model.

Ailane N, Greco C, Zhu Y, Sala-Valdés M, Billard M, Casal I, Bawa O, Opolon P, Rubinstein E, Boucheix C.

Front Physiol. 2014 Sep 19;5:364. doi: 10.3389/fphys.2014.00364. eCollection 2014.

19.

Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Favalli EG, Bugatti S, Biggioggero M, Caporali R.

Biomed Res Int. 2014;2014:831603. doi: 10.1155/2014/831603. Epub 2014 Apr 16. Review.

20.

Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.

Feigelson HS, Zeng C, Pawloski PA, Onitilo AA, Richards CS, Johnson MA, Kauffman TL, Webster J, Nyirenda C, Alexander GL, Hwang C, Cross D, McCarty CA, Davis RL, Schwarzkopf D, Williams AE, Honda S, Daida Y, Kushi LH, Delate T, Goddard KA; CERGEN Study Team..

PLoS One. 2014 May 1;9(5):e94977. doi: 10.1371/journal.pone.0094977. eCollection 2014.

Supplemental Content

Support Center